1,2,4,5-tetrahydrobenzo[d]azepine-3-carboxylic acid ethyl ester | 1334433-20-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 1,2,4,5-tetrahydrobenzo[d]azepine-3-carboxylic acid ethyl ester
• 英文别名: ethyl 1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate；ethyl 1,2,4,5-tetrahydro-3-benzazepine-3-carboxylate
• CAS: 1334433-20-3
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: HJWLCKRMBWFGKM-UHFFFAOYSA-N

物化性质

• 沸点：
  335.0±31.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2,4,5-tetrahydrobenzo[d]azepine-3-carboxylic acid ethyl ester 在 aluminum (III) chloride 、 N-碘代丁二酰亚胺 、 草酰氯 、 5%-palladium/activated carbon 、 palladium 10% on activated carbon 、 叔丁基二甲硅基三氟甲磺酸酯 、 氢溴酸 、 氢气 、 溴 、 溶剂黄146 、 Selectfluor 、 三乙胺 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 、 N,N'-羰基二咪唑 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 60.0 ℃ 、344.75 kPa 条件下， 反应 97.67h， 生成 2,2-difluoro-1-oxo-1,3,6,7,9,10-hexahydro-2H-8-azacyclohepta[e]indene-8-carboxylic acid benzyl ester
  参考文献：
  名称：

  [EN] BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF
  [FR] BENZAZÉPINES EN TANT QUE LIGANDS DU RÉCEPTEUR 5-HT2C DE LA SÉROTONINE ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2014100815A3
• 作为产物：
  描述：

  2,3,4,5-四氢-1H-苯并[D]氮杂卓(盐酸盐) 、 氯甲酸乙酯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以5.5 g的产率得到1,2,4,5-tetrahydrobenzo[d]azepine-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF
  [FR] BENZAZÉPINES EN TANT QUE LIGANDS DU RÉCEPTEUR 5-HT2C DE LA SÉROTONINE ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2014100815A3

文献信息

• Benzazepine Compound
  申请人：KOSHIO Hiroyuki

  公开号：US20110269744A1

  公开（公告）日：2011-11-03

  [Problem] Provided is a compound which is useful as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. [Means for Solution] The present inventors have investigated compounds having a 5-HT 2C receptor agonist activity, which is promising as an active ingredient of a pharmaceutical composition for treating or preventing incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like, and have found that the benzazepine compounds of the present invention have an excellent 5-HT 2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT 2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

  提供的是一种化合物，可用作治疗或预防与5-HT 2C 受体相关的疾病的药剂，特别是尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等。 【解决方案】本发明者研究了具有5-HT 2C 受体激动剂活性的化合物，这种活性有望作为治疗或预防尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等的药物组合物的有效成分。他们发现本发明的苯并环己酮类化合物具有出色的5-HT 2C 受体激动剂活性，从而完成了本发明。换句话说，本发明的苯并环己酮类化合物具有5-HT 2C 受体激动剂活性，可用作治疗或预防与5-HT 2C 受体相关的疾病的药剂，特别是尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等。
• BENZAZEPINE COMPOUND
  申请人：Koshio Hiroyuki

  公开号：US20130012496A1

  公开（公告）日：2013-01-10

  Provided is a compound which is useful as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT 2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT 2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT 2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

  提供了一种化合物，可用作治疗或预防5-HT2C受体相关疾病的药剂，特别是尿失禁，如压力性尿失禁，切勿性尿失禁，混合性尿失禁等，性功能障碍，如勃起功能障碍综合症等，肥胖症等。本发明人研究了具有5-HT2C受体激动剂活性的化合物，并发现本发明的苯并氮杂环化合物具有优异的5-HT2C受体激动剂活性，从而完成了本发明。也就是说，本发明的苯并氮杂环化合物具有5-HT2C受体激动剂活性，并可用作治疗或预防5-HT2C受体相关疾病的药剂，特别是尿失禁，如压力性尿失禁，切勿性尿失禁，混合性尿失禁等，性功能障碍，如勃起功能障碍综合症等，肥胖症等。
• BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF
  申请人：ABT Holding Company

  公开号：US20140194411A1

  公开（公告）日：2014-07-10

  The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are benzazepine compounds. These compounds are serotonin receptor (5-HT 2c ) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT 2c ) is desired (e.g. addiction, anxiety, depression, obesity, and others).

  本发明一般涉及一系列化合物，含有这些化合物的药物组合物，以及将这些化合物和组合物用作治疗剂。更具体地，本发明的化合物是苯并咪唑化合物。这些化合物是血清素受体（5-HT2c）配体，对于治疗需要调节血清素受体（5-HT2c）活性的疾病、障碍和病况（例如成瘾、焦虑、抑郁、肥胖等）非常有用。
• Benzazepine compound
  申请人：Koshio Hiroyuki

  公开号：US09108977B2

  公开（公告）日：2015-08-18

  Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

  提供了一种化合物，可作为治疗或预防5-HT2C受体相关疾病的药物，特别是治疗失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖症等。本发明人研究了具有5-HT2C受体激动剂活性的化合物，并发现本发明的苯并氮杂环化合物具有优异的5-HT2C受体激动剂活性，从而完成了本发明。也就是说，本发明的苯并氮杂环化合物具有5-HT2C受体激动剂活性，可作为治疗或预防5-HT2C受体相关疾病的药物，特别是治疗失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖症等。
• Benzazepines as serotonin 5-HT2C receptor ligands and uses thereof
  申请人：ABT Holding Company

  公开号：US09284277B2

  公开（公告）日：2016-03-15

  The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are benzazepine compounds. These compounds are serotonin receptor (5-HT2c) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).

  本发明一般涉及一系列化合物，包括含有这些化合物的药物组合物，以及将这些化合物和组合物用作治疗剂。更具体地说，本发明的化合物是苯并氮杂环化合物。这些化合物是5-羟色胺受体（5-HT2c）配体，可用于治疗需要调节5-羟色胺受体（5-HT2c）活性的疾病、障碍和病况（例如成瘾、焦虑、抑郁、肥胖等）。